Evidence map›Paper›PMID 37274824›Full record

ArticleFrontiers in pediatrics2023

Characteristics and outcomes of multisystem inflammatory syndrome in children: A multicenter, retrospective, observational cohort study in Mexico.

Marco Antonio Yamazaki-Nakashimada, Horacio Márquez-González, Guadalupe Miranda-Novales, Gonzalo Antonio Neme Díaz, Sandhi Anel Prado Duran, Antonio Luévanos Velázquez, Maria F Castilla-Peon, Nadia González-García, Miguel Alejandro Sánchez Duran, Martha Patricia Márquez Aguirre and 14 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pediatrics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 7 institutions in 1 country.

Marco Antonio Yamazaki-NakashimadaNational Institute of Pediatrics, Mexico City, Mexico.
Horacio Márquez-GonzálezDepartment of Rheumatology, Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico.
Guadalupe Miranda-NovalesXXI Century National Medical Center, Mexican Social Security Institute, Mexico City, Mexico.
Gonzalo Antonio Neme DíazHospital del Niño Dr. Rodolfo Nieto Padrón, Villahermosa, Mexico.
Sandhi Anel Prado DuranMexican Social Security Institute (IMSS), Mexico City, Mexico.
Antonio Luévanos VelázquezCivil Hospital of Guadalajara, Guadalajara, Mexico.
Maria F Castilla-PeonHospital Psiquiatrico Infantil Juan N Navarro, Servicios de Atención Psiquiátrica, Mexico City, Mexico.
Nadia González-GarcíaDepartment of Rheumatology, Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico.
Miguel Alejandro Sánchez DuranNational Institute of Pediatrics, Mexico City, Mexico.
Martha Patricia Márquez AguirreNational Institute of Pediatrics, Mexico City, Mexico.
Miguel Angel Villasis-KeeverXXI Century National Medical Center, Mexican Social Security Institute, Mexico City, Mexico.
Ranferi Aragón NogalesXXI Century National Medical Center, Mexican Social Security Institute, Mexico City, Mexico.
Juan Carlos Núñez-EnríquezXXI Century National Medical Center, Mexican Social Security Institute, Mexico City, Mexico.
Maria Elena Martinez BustamanteCentro Médico Nacional 20 de Noviembre (CMN), Mexico City, Mexico.
Carlos Aguilar ArgüelloHospital del Niño Dr. Rodolfo Nieto Padrón, Villahermosa, Mexico.
Jesús Ramírez de Los SantosHospital del Niño Dr. Rodolfo Nieto Padrón, Villahermosa, Mexico.
Alejandra Pérez BarreraHospital del Niño Dr. Rodolfo Nieto Padrón, Villahermosa, Mexico.
Lourdes Anais Palacios CantúMexican Social Security Institute (IMSS), Mexico City, Mexico.
Jesús Membrila MondragónMexican Social Security Institute (IMSS), Mexico City, Mexico.
Paloma Vizcarra AlvaradoCivil Hospital of Guadalajara, Guadalajara, Mexico.
Rodolfo Norberto Jiménez JuárezDepartment of Rheumatology, Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico.
Víctor Olivar LópezDepartment of Rheumatology, Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico.
Roberto Velasco-SeguraInstituto de Ciencias Aplicada y Tecnología, Universidad Nacional Autónoma de México, Mexico City, Mexico.
Adrián López ChávezDepartment of Rheumatology, Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico.
Mexican Social Security Institute · MXHospital Infantil de México Federico Gómez · MXTecnológico Nacional de México · MXHospital Civil de Guadalajara · MXCentro Medico Nacional Siglo XXI · MXHospital Psiquiatrico Infantil Juan N Navarro · MXUniversidad Nacional Autónoma de México · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Multisystem inflammatory syndrome in children associated with coronavirus disease 2019 (MIS-C), a novel hyperinflammatory condition secondary to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, is associated with severe outcomes such as coronary artery aneurysm and death. Methods: This multicenter, retrospective, observational cohort study including eight centers in Mexico, aimed to describe the clinical characteristics and outcomes of patients with MIS-C. Patient data were evaluated using latent class analysis (LCA) to categorize patients into three phenotypes: toxic shock syndrome-like (TSSL)-MIS-C, Kawasaki disease-like (KDL)-MIS-C, and nonspecific MIS-C (NS-MIS-C). Risk factors for adverse outcomes were estimated using multilevel mixed-effects logistic regression. Results: The study included 239 patients with MIS-C, including 61 (26%), 70 (29%), and 108 (45%) patients in the TSSL-MIS-C, KDL-MIS-C, and NS-MIS-C groups, respectively. Fifty-four percent of the patients were admitted to the intensive care unit, and 42%, 78%, and 41% received intravenous immunoglobulin, systemic glucocorticoids, and anticoagulants, respectively. Coronary artery dilatation and aneurysms were found in 5.7% and 13.2% of the patients in whom coronary artery diameter was measured, respectively. Any cause in-hospital mortality was 5.4%. Hospitalization after ten days of symptoms was associated with coronary artery abnormalities (odds ratio [OR] 1.6, 95% confidence interval [CI] 1.2-2.0). Age ≥10 years (OR: 5.6, 95% CI: 1.4-2.04), severe underlying condition (OR: 9.3, 95% CI: 2.8-31.0), platelet count <150,000 /mm Discussion: Mortality in patients with MIS-C was higher than reported in other series, probably because of a high rate of cases with serious underlying diseases.

Indexed as

coronary aneurismcoronavirus disease (COVID)-19Mexicomulticenter studymultisystem inflammatory syndromepediatricsevere acute respiratory syndrome coronavirus (SARS-CoV)

Identifiers

PMID37274824
PMCPMC10233130
OpenAlexW4377103833

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.